Science News
from research organizations

Expert opinion on how to address the skyrocketing prices of cancer drugs

Date:
February 12, 2016
Source:
Fred Hutchinson Cancer Research Center
Summary:
Many patients with cancer find themselves in great financial distress, in part because the costs of cancer-fighting drugs are skyrocketing. Is it possible to create public policy that will rein in these prices and cut patients' out-of-pocket costs? Not without significant tradeoffs, that could reduce patients' access to some cancer medications, says a physician, cancer researcher and health economist.
Share:
FULL STORY

Many patients with cancer find themselves in great financial distress, in part because the costs of cancer-fighting drugs are skyrocketing. Is it possible to create public policy that will rein in these prices and cut patients' out-of-pocket costs?

Not without significant tradeoffs that could reduce patients' access to some cancer medications, says physician, cancer researcher and health economist Dr. Scott Ramsey in a JAMA Oncology editorial.

Ramsey, director of the Hutchinson Institute for Cancer Outcomes Research, and two colleagues propose three policy interventions: 1) public and private health insurers must have the ability to negotiate prices with manufacturers, 2) insurers need the ability to withhold products from formularies if drug prices do not represent good value, and 3) there must be greater transparency of cancer drug pricing and better information about treatment choices.

"The current model for cancer drug pricing is not sustainable and harms patients and families as well as our health care system," the authors said. "Solutions are possible that better balance access, affordability and incentives to innovate, but, by necessity, will create situations where low-value drugs are not available except outside of the insurance system. Whether society will accept that 'pain' for the gain of a more equitable and sustainable cancer drug market remains to be seen."

The editorial, "Pick Your Poison: Addressing Skyrocketing Cancer Drug Prices Comes with Tradeoffs," is online Feb. 11, 2016.

Ramsey and his colleagues at the Fred Hutchinson Cancer Research Center, have extensively studied the financial impact of a cancer diagnosis. In 2013, they reported that patients diagnosed with cancer were 2.5 times more likely to file for bankruptcy than those not diagnosed with the disease. Last month, they published in the Journal of Clinical Oncology that cancer patients who file for bankruptcy have a significantly higher risk of dying than those in less financial distress. In some types of cancer, the risk was more than doubled.


Story Source:

The above post is reprinted from materials provided by Fred Hutchinson Cancer Research Center. Note: Materials may be edited for content and length.


Journal References:

  1. Joseph M. Unger, Julie R. Gralow, Kathy S. Albain, Scott D. Ramsey, Dawn L. Hershman. Patient Income Level and Cancer Clinical Trial Participation. JAMA Oncology, 2016; 2 (1): 137 DOI: 10.1001/jamaoncol.2015.3924
  2. Scott D. Ramsey, Gary H. Lyman, Rick Bangs. Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs. JAMA Oncology, 2016; DOI: 10.1001/jamaoncol.2015.5813

Cite This Page:

Fred Hutchinson Cancer Research Center. "Expert opinion on how to address the skyrocketing prices of cancer drugs." ScienceDaily. ScienceDaily, 12 February 2016. <www.sciencedaily.com/releases/2016/02/160212091628.htm>.
Fred Hutchinson Cancer Research Center. (2016, February 12). Expert opinion on how to address the skyrocketing prices of cancer drugs. ScienceDaily. Retrieved July 29, 2016 from www.sciencedaily.com/releases/2016/02/160212091628.htm
Fred Hutchinson Cancer Research Center. "Expert opinion on how to address the skyrocketing prices of cancer drugs." ScienceDaily. www.sciencedaily.com/releases/2016/02/160212091628.htm (accessed July 29, 2016).

Share This Page: